Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food ...
UCB secured worldwide exclusive rights to develop, manufacture, and commercialize ATG-201, including access to Antengene’s enabling manufacturing technology for this bispecific T-cell engager modality ...
Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific ...
Glucocorticoids and B-cell targeting therapies are the cornerstones of IgG4 disease treatment, according to data presented at ...
Dr.Thomas L. F. Montgomery Andresen joins from T-Cypher BioFollows breakthrough non-human primate data demonstrating deep B-cell depletion without cytokine releaseCommit is poised to nominate its ...
Initial clinical response data for AlloNK in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food and Drug Administration (FDA) interaction to discuss potential pivotal trial ...
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell ...
Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026Zipalertinib rolling NDA ...
The funding will support scaling industrial battery production and advancing proprietary electrode technologies designed for ...
Leerink Global Healthcare Conference 2026 March 11, 2026 9:20 AM EDTCompany ParticipantsJasper Van GrunsvenPeter Griffith - Executive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results